Judes Poirier PhD, CQ
- Theme-Based Group:Aging, Cognition, and Alzheimer’s Disease
- Division:Human Neuroscience
6875 Boulevard LaSalle
Researcher, Douglas Research Centre
Director, Molecular Neurobiology Unit, Douglas Research Centre
Full Professor, Department of Medicine, McGill University
Full Professor, Department of Psychiatry, McGill University
Alzheimer's disease genetics research
ADGEN: Alzheimer's Disease Genetics Research Unit
Under the leadership of Dr. Judes Poirier, C.Q., ADGEN is a research unit dedicated to the understanding of the genetics and molecular neurobiology of dementing illnesses such as Alzheimer's disease (AD) and Vascular dementia (VD). It's research strategy is focused on the use of a broad class of drugs, which ADGEN refers to as "apolipoprotein E inducers", in the treatment and prevention of neurodegenerative diseases such as AD. There is an estimated 6 million persons suffering from Alzheimer's disease in North America ( > 36 million worldwide) and twice as many who are "at risk" of developing the disease in the next 15 years. ADGEN's research team believes that its patented technologies and research approaches represent major advancements in the fight against dementias. It is estimated that more than $200 billion dollars are spent every year on direct and indirect health care cost and lost working days in North America because of Alzheimer's disease. Our pioneering work on the role of genetic risk factors in disease etiology and therapy has allowed us to identify several genetic variants that affect either, the age of onset, the rate of progression or the quality of the drug response to memory enhancer medications. The most common genetic defect identified so far involves a critical transporter of brain cholesterol called apolipoprotein E (apoE) and a neurotransmitter degrading enzyme called butyrylcholinesterase (BuChE). Using unique genetic signatures, we have characterized the biological functions of key modulators of lipid physiology in the brain and screened a large number of chemical entities capable of restoring impaired lipid homeostasis in the brain of affected AD subjects. This pioneering work led to the successful identification of several potential pharmacological targets, including a few potent apoE inducers. In recent year, we have chosen to focus on a particular compound which was used several years ago to lower blood cholesterol in humans. This led to the development of an extensive pre- clinical research program in brain rodent and human cell cultures, mice and rat models, and more importantly, to a small proof-of-principle clinical trial in humans suffering from mild-to- moderate AD. Final results clearly indicate that it is possible to modify the brain's lipid chemistry and to enhance lipid mobilisation, to slow down disease progression and to reduce the burden of toxic brain byproducts such as phospho-Tau, a protein commonly associated with AD pathology. Recently, Pfizer and Eli Lilly have expressed interested in the lipid transporter-based therapy field by launching new, but small, initiatives to tackle this emerging field of research in AD. Although there are a few medications designed to improve memory deficits in AD subjects, none of these treatments halt or slow down the progression, or delay onset of the disease in a significant manner. At best, the clinical benefits last 6 to 18 months, and only in a modest subset of patients. Furthermore, recent attempts by small and large pharmaceutical corporations to interfere with one of Alzheimer’s pathological hallmark called amyloid by means of vaccines (Elan, Wyett-Ayerst), inhibitors of synthesis (Astrazeneca, SKB, GSK and Ely Lilly) and disaggregating agents (Parke-Davis, Neurochem) have failed so far to meet FDA requirements.
Brain Reinnervation and Apolipoprotein E Neurobiology
The initial phase of our research program has been to identify key mRNAs involved in synaptic remodelling in the injured adult rodent brain. In an article published in Proc. Natl. Acad. Sci. 87:303, we documented the fact that a limited numbers of mRNAs of moderate prevalence exhibit significant induction during the active phase of reinnervation in the experimentally deafferented rat hippocampus (a partial model of Alzheimer's disease pathology). The most important transcript identified during follow-up cDNA screenings turned out to be a protein known as apolipoprotein E (apoE), a well-characterized cholesterol transporter produced locally in the brain.
Apolipoprotein E4 and the Pathophysiology of Alzheimer’s disease
In a series of follow-up studies in neurodegenerative diseases, we published a breakthrough report in the Lancet 342: 697 where we reported that sporadic cases with Alzheimer's disease (AD) exhibit an abnormally high incidence of a normally rare apoE allele referred to as the apoE4. Follow-up publications by our team demonstrated a potent apoE4-gene dose effect on : a) age of onset, b) rate of progression, c) risk of developing the disease and more importantly, d) on the cholinergic status and integrity in the brain of sporadic Alzheimer’s disease subjects: Proc. Natl. Acad. Sci. 92: 12260, Lancet 347: 1091, J.A.M.A. 278: 1349, Proc. Natl. Acad. Sci. 98: 10966.
Apolipoprotein E influences the Beta-Amyloid Neurotoxicity and Metabolism
In more recent years, we uncovered the biological connection linking the so-called beta amyloid cascade hypothesis of AD and apolipoprotein E metabolism in the pathophysiology of Alzheimer’s disease. Using various techniques, models and approaches, we documented the apoE/beta amyloid relationship in vitro and in vivo. The studies were published in Nature 387: 500, J. Neurochem. 66:2410, J. Neurochem. 70:1466, Brain Research Reviews 27: 199 Apolipoprotein E4: A Pharmacogenomic Marker of Drug Efficacy in Alzheimer’s disease: Our modest but significant contribution to the emerging field of the pharmacogenomics prompted several pharmaceutical corporations (Eli Lilly, Bayer, Parke Davis, Novartis and Smith Kline Beecham) to re-evaluate their clinical drug trial designs to include an apoE genotype arm. We and others have documented on multiple occasions the fact that the efficacy of several memory enhancers (especially cholinomimetics) are highly dependent upon the individual’s apoE or BuChE K genotypes Proc. Natl. Acad. Sci. 92: 12260, Neurology 50: 669, Curr. Pharmacogen. 8: 63 this key contribution to canadian translation research effort was recognized by the Galien 1996 Prize and Genesis Awards 2010 Cholesterol Metabolism as Therapeutic Target for the Treatment of Alzheimer’s Disease: As early as 1993, we proposed that the reduction in apoE concentrations reported in the blood and brain of apoE4 allele carriers could be alleviated by drugs that specifically promote apoE synthesis and secretion in the CNS. Building on the approach, we identified three different agents (out of several hundreds) with strong apoE inducing capacity: estrogen, indomethacin and probucol (Eur. J. Neurosci. 18: 1, Neuroscience 121: 99, Alz. Dem. 4: 591, Curr Alz Res 5:33) . Independently of this work, these three compounds had been shown to reduce the risk of developing AD in several epidemiological studies ran in the US, Europe and Asia. As a consequence, we choose to focus on the drug Probucol, a potent cholesterol-lowering agent for efficacy and safety reasons. In a small proof-of-principal study performed in Montreal (Adv. Behav. Biol. 51: 39, Trends Mol. Medicine 9:94, Neurobiol. Aging 2014), we discovered that a 6-month treatment with Probucol in mild-to-moderate AD stopped disease progression in the majority of the 12 patients enrolled in the study and “improved” the activities of daily living for the entire group.
Dr. Poirier received his undergraduate training at the “Université de Montréal” in biochemistry. Shortly after, he joined Dr. André Barbeau’s group at the Clinical Research Institute of Montreal where he completed his Ph.D. on the neurobiology of Parkinson’s disease and the neurotoxicity of MPTP and Aluminum. He was then invited to join the Alzheimer’s Disease Research Consortium of Southern California in Los Angeles as research associate. It is in California that he discovered the important role of apolipoprotein E, a key cholesterol trans-porter that acts as a powerful modulator of brain repair and, serves as a key player in Alzheimer’s disease pathophysiology. McGill University and the Douglas Institute recruited him back in the spring of 89 to establish a research program specialised in neurodegenerative diseases with a strong focus on Alzheimer’s disease genetics.
1990 GSK Fellowship, Glaxo Canada
1991 Fidia/ISN Award
1993 Merit Award, Parkinson Foundation of Canada
1993 Top 10 discovery of the Year, Quebec Science magazine.
1994 Claude Beaubien Award of Excellence, Alzheimer Society of Canada
1994 CCNP Investigator Award, Canadian College for Neuropsychopharmacology
1994-1998 FRSQ Career Award, Fonds de la Recherche en Santé du Québec
1995 ISN Young Scientist Award, International Society for Neurochemistry, Japan
1995 Personality of the Year, “L’actualité” magazine
1996 Parke Davis / ICAD Award, Parke-Davis/Warnet Lambert Corporation, Japan
1997 Galien Award, Pharmaceutical Manufacturer Association of Canada
1998 MRCC Scientist Award, Medical Research Council of Canada
1998 Prix André Dupont, Club de Recherches Cliniques du Québec
1998 CCNP Innovation Award, Canadian College for Neuropsychopharmacology
1998 Personality of the Week “La Presse”, Newspaper
1999 Jonas Salk Award, March of Dime, Canada
2001/2003 Astra Zeneca Research Award, Astra Zeneca US
2001 CSCC Pharmacogenomic Award, Canadian Society for Clinical Chemistry, Chicago
2003 CIHR Senior Scientist Award, Canadian Institute on Health Research
2004 Knight, National Order of Québec, Quebec Government, Premier’s Executive Council
2009 Doctor of Medicine, Honoris Causa, Faculty of Medicine, University of Montpellier, France
2010 Genesis Prize 2010, Genome Canada and BioQuébec.
2012 Hubert-Reeves Prize, Canadian Association of Scientific journalists.
2014 Personality of the Week “La Presse”, Newspaper.
2015 Top 10 discovery of the Year, Quebec Science magazine.
Mrs Doris Dea, Laboratory manager and senior research assistant
Mrs. Louise Théroux, Bioanalytical research coordinator and senior research assistant
Mrs. Anne Labonté, Biomarkers research coordinator, senior research assistant
Mrs. Josée Frappier, Gene Expression coordinator, senior research assistant
Dr. Cynthia Picard, Geneticist and GWAS Coordinator, Post-doctoral fellow
Dr. Sandra Peilleux, Pharmacologist, Post-doctoral fellow
Justin Miron, Biochemist, Ph.D. student
Valerie Leduc, Biochemist, MD/Ph.D. student
Nathalie Nilssen, Biochemist, Ph.D. student
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimers Dement. 2021.
Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nat Commun. 2021;12(1):5346.
Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. Neuroimage Clin. 2021;31:102733.
Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease. Neurology. 2020;95(11):e1554-e1564.
APOEε4 potentiates the relationship between amyloid-β and tau pathologies. Mol Psychiatry. 2020.
Morphometric network differences in ageing versus Alzheimer's disease dementia. Brain. 2020;143(2):635-649.
Cerebral white matter diffusion properties and free-water with obstructive sleep apnea severity in older adults. Human brain mapping. 2020;41(10):2686-2701.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study. PLoS ONE. 2019;14(8):e0220254.
Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology. Alzheimers Dement. 2019;15(9):1160-1171.
Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. Neurobiol Aging. 2019;81:234-243.
The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Can J Neurol Sci. 2019;46(5):499-511.
No apparent effect of naproxen on CSF markers of innate immune activation. Ann Clin Transl Neurol. 2019;6(6):1127-1133.
Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. Alzheimers Dement. 2019;15(7):951-960.
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019;15(6):742-753.
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2019;92(18):e2070-e2080.
TLR4 Gene Expression and Pro-Inflammatory Cytokines in Alzheimer's Disease and in Response to Hippocampal Deafferentation in Rodents. J Alzheimers Dis. 2018;63(4):1547-1556.
Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease. Brain. 2018;141(6):1871-1883.
Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. J Alzheimers Dis. 2018;63(2):577-590.
Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease. J Geriatr Psychiatry Neurol. 2018;31(2):90-96.
- 1 of 3